title: Novel strategy for the treatment of refractory vasculitis syndrome.
abstract: The recent development of biologic therapies capable of selectively targeting components of the immune system has revolutionized the treatment of inflammatory arthritides. The increase in the use of biologic agents coupled with expansion in the knowledge of the pathogenesis of vascular inflammation has led to their application in the treatment of primary systemic vasculitis. Biological therapies appear to have a place in the therapeutic strategy for ANCA-associated systemic vasculitides, at least for patients whose disease is refractory to conventional therapy. The use of biologics as targeted therapies has also, in reverse, improved our understanding of the pathophysiology of vascular inflammation. However, the precise indications for TNF-alpha inhibitors or anti-CD20 monoclonal antibodies have not yet been defined. These biologics must be prescribed extremely cautiously and only in trial settings, especially in view of the adverse effects. (*English Translation of J Jpn Coll Angiol, 2009, 49: 75-79).
authors: Division of Rheumatology, Department of Internal Medicine, St. Marianna Medical School, Kanagawa, Japan.
authors: Hidehiro
authors: H
authors: Yamada
keywords: ANCA-associated vasculitis; TNF-α-antagonists; Takayasu’s arteritis; rituximab
references: N Engl J Med. 2005 Jan 27;352(4):351-61
references: 15673801
references: Intern Med. 2006;45(5):313-6
references: 16596001
references: Ann Rheum Dis. 2002 Jun;61(6):559
references: 12006335
references: Rheumatology (Oxford). 2002 Oct;41(10):1126-32
references: 12364631
references: Arthritis Rheum. 2008 Apr;58(4):1197-200
references: 18383395
references: Rheumatology (Oxford). 2006 Nov;45(11):1432-6
references: 16632482
references: Am J Med. 1979 Dec;67(6):941-7
references: 42314
references: J Clin Rheumatol. 2005 Aug;11(4):213-5
references: 16357759
references: Arthritis Rheum. 2005 Jan;52(1):262-8
references: 15641078
references: Rheumatology (Oxford). 2004 Dec;43(12):1532-5
references: 15316126
references: Ann Intern Med. 1983 Jan;98(1):76-85
references: 6336643
references: Rheumatology (Oxford). 2002 Nov;41(11):1303-7
references: 12422004
references: Arthritis Rheum. 2004 Jul;50(7):2296-304
references: 15248230
references: Clin Rheumatol. 2007 May;26(5):821-2
references: 16575491
references: Clin Rheumatol. 2007 Jun;26(6):984-7
references: 16633710
references: J Am Soc Nephrol. 2004 Mar;15(3):717-21
references: 14978174
references: Int J Cancer. 2002 Jul 1;100(1):82-5
references: 12115591
references: Am J Respir Crit Care Med. 2006 Jan 15;173(2):180-7
references: 16224107
references: Ann Rheum Dis. 2007 Apr;66(4):564-5
references: 17360788
references: Ann Intern Med. 2007 May 1;146(9):621-30
references: 17470830
references: Rheumatology (Oxford). 2005 Aug;44(8):1074-5
references: 15840604